Eithan Kotkowski1, John H Cabot2, John V Lacci2, Davis H Payne2, Jose E Cavazos3, Rebecca S Romero4, Ali Seifi5. 1. Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; University of Texas Health Science Center at San Antonio Long School of Medicine, San Antonio, TX, USA. 2. University of Texas Health Science Center at San Antonio Long School of Medicine, San Antonio, TX, USA. 3. University of Texas Health Science Center at San Antonio Long School of Medicine, San Antonio, TX, USA; University of Texas Health Science Center at San Antonio Department of Neurology, San Antonio, TX, USA. 4. University of Texas Health Science Center at San Antonio Long School of Medicine, San Antonio, TX, USA; University of Texas Health Science Center at San Antonio Department of Neurology, San Antonio, TX, USA; Comprehensive Multiple Sclerosis Clinic at the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 5. University of Texas Health Science Center at San Antonio Long School of Medicine, San Antonio, TX, USA; Department of Neurosurgery, Neurology, and Anesthesiology at University Health System, San Antonio, TX, USA. Electronic address: seifi@uthscsa.edu.
Abstract
BACKGROUND: This report highlights a rapidly progressive case of Creutzfeldt-Jakob Disease (CJD) whose time from symptom onset to death spanned less than two months. We also explore the most recently available in-patient demographics data for discharges with CJD in the United States. METHODS: We reviewed a CJD case and systematically analyzed a retrospective cohort of CJD discharges using the Healthcare Cost and Utilization Project (HCUP) to evaluate the existing national data on the status of CJD demographics and dispositions in the United States in 2016. RESULTS: An estimated total of 710 hospital discharges with a diagnosis of CJD were seen across the United States in 2016. According to HCUP, the average age of patients was 66.15 ± 11.54 years with 48.6 % female. Average time to intubation from admission to hospital was 4.71 ± 7.32 days with a rate of intubation of 6.34 %. The mean hospital cost was $19,901.25 ± $18,743.48. The rate of in-hospital mortality was 8.45 %. No significant geographical differences were noted (p = 0.49). No significant differences were seen among incidence in specific ethnic groups (p = 0.33) or income quartiles (p = 0.90). CONCLUSIONS: Our data shows that the incidence of CJD in 2016 appears to be equally distributed among individuals in the United States by demographic categories. Additionally, our case-study from 2019 illustrates an important example for diagnosing a rapidly-progressing case of CJD.
BACKGROUND: This report highlights a rapidly progressive case of Creutzfeldt-Jakob Disease (CJD) whose time from symptom onset to death spanned less than two months. We also explore the most recently available in-patient demographics data for discharges with CJD in the United States. METHODS: We reviewed a CJD case and systematically analyzed a retrospective cohort of CJD discharges using the Healthcare Cost and Utilization Project (HCUP) to evaluate the existing national data on the status of CJD demographics and dispositions in the United States in 2016. RESULTS: An estimated total of 710 hospital discharges with a diagnosis of CJD were seen across the United States in 2016. According to HCUP, the average age of patients was 66.15 ± 11.54 years with 48.6 % female. Average time to intubation from admission to hospital was 4.71 ± 7.32 days with a rate of intubation of 6.34 %. The mean hospital cost was $19,901.25 ± $18,743.48. The rate of in-hospital mortality was 8.45 %. No significant geographical differences were noted (p = 0.49). No significant differences were seen among incidence in specific ethnic groups (p = 0.33) or income quartiles (p = 0.90). CONCLUSIONS: Our data shows that the incidence of CJD in 2016 appears to be equally distributed among individuals in the United States by demographic categories. Additionally, our case-study from 2019 illustrates an important example for diagnosing a rapidly-progressing case of CJD.
Authors: Michael D Geschwind; Amy L Kuo; Katherine S Wong; Aissa Haman; Gillian Devereux; Benjamin J Raudabaugh; David Y Johnson; Charles C Torres-Chae; Ron Finley; Paul Garcia; Julie N Thai; Hugo Q Cheng; John M Neuhaus; Sven A Forner; Jacque L Duncan; Katherine L Possin; Stephen J Dearmond; Stanley B Prusiner; Bruce L Miller Journal: Neurology Date: 2013-10-11 Impact factor: 9.910
Authors: Clive Hamlin; Gianfranco Puoti; Sally Berri; Elliott Sting; Carrie Harris; Mark Cohen; Charles Spear; Alberto Bizzi; Sara M Debanne; Douglas Y Rowland Journal: Neurology Date: 2012-07-25 Impact factor: 9.910
Authors: Daniel D Rhoads; Aleksandra Wrona; Aaron Foutz; Janis Blevins; Kathleen Glisic; Marissa Person; Ryan A Maddox; Ermias D Belay; Lawrence B Schonberger; Curtis Tatsuoka; Mark L Cohen; Brian S Appleby Journal: Neurology Date: 2020-06-22 Impact factor: 9.910
Authors: M Otto; L Cepek; P Ratzka; S Doehlinger; I Boekhoff; J Wiltfang; E Irle; G Pergande; B Ellers-Lenz; O Windl; H A Kretzschmar; S Poser; H Prange Journal: Neurology Date: 2004-03-09 Impact factor: 9.910
Authors: I Zerr; K Kallenberg; D M Summers; C Romero; A Taratuto; U Heinemann; M Breithaupt; D Varges; B Meissner; A Ladogana; M Schuur; S Haik; S J Collins; Gerard H Jansen; G B Stokin; J Pimentel; E Hewer; D Collie; P Smith; H Roberts; J P Brandel; C van Duijn; M Pocchiari; C Begue; P Cras; R G Will; P Sanchez-Juan Journal: Brain Date: 2009-09-22 Impact factor: 13.501